Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1997 1
2001 3
2002 1
2003 2
2004 6
2005 6
2006 15
2007 12
2008 12
2009 35
2010 40
2011 40
2012 44
2013 38
2014 33
2015 23
2016 21
2017 12
2018 7
2019 4
2020 3
2021 1
2022 3
2023 6
2024 2
2025 8
2026 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

328 results

Results by year

Filters applied: . Clear all
Page 1
Morning vs Bedtime Dosing and Nocturnal Blood Pressure Reduction in Patients With Hypertension: The OMAN Randomized Clinical Trial.
Ye R, Yang X, Zhang X, Zuo X, Li Y, Jia S, Xu M, Liu L, Wang S, Liu K, Meng Q, Liao H, Zhang Z, Shi R, Li X, Liu X, Sun L, Zhang X, Ran Q, Chen F, Gao Q, Yao W, Shi H, Liu T, Ma K, Liu L, Chen K, Gao J, Chen X. Ye R, et al. JAMA Netw Open. 2025 Jul 1;8(7):e2519354. doi: 10.1001/jamanetworkopen.2025.19354. JAMA Netw Open. 2025. PMID: 40632538 Free PMC article. Clinical Trial.
INTERVENTIONS: Patients received a single pill containing olmesartan, 20 mg, and amlodipine, 5 mg, daily for 12 weeks, with dosage adjustments based on ambulatory and office blood pressure measurements at week 4 and week 8. ...
INTERVENTIONS: Patients received a single pill containing olmesartan, 20 mg, and amlodipine, 5 mg, daily for 12 weeks, with dosage ad …
Add-On Treatment With Zilebesiran for Inadequately Controlled Hypertension: The KARDIA-2 Randomized Clinical Trial.
Desai AS, Karns AD, Badariene J, Aswad A, Neutel JM, Kazi F, Park W, Stiglitz D, Makarova N, Havasi A, Zappe DH, Saxena M; KARDIA-2 Study Group. Desai AS, et al. JAMA. 2025 Jul 1;334(1):46-55. doi: 10.1001/jama.2025.6681. JAMA. 2025. PMID: 40434761 Free PMC article. Clinical Trial.
RESULTS: Of 1491 patients entering the run-in phase, 663 (130 receiving indapamide, 240 receiving amlodipine, and 293 receiving olmesartan) were randomized to receive zilebesiran (n = 332) or placebo (n = 331). The least-squares mean difference between zilebesiran and plac …
RESULTS: Of 1491 patients entering the run-in phase, 663 (130 receiving indapamide, 240 receiving amlodipine, and 293 receiving olmesarta …
Efficacy of sacubitril/valsartan versus olmesartan in Japanese patients with essential hypertension: a randomized, double-blind, multicenter study.
Rakugi H, Kario K, Yamaguchi M, Sasajima T, Gotou H, Zhang J. Rakugi H, et al. Hypertens Res. 2022 May;45(5):824-833. doi: 10.1038/s41440-021-00819-7. Epub 2022 Jan 21. Hypertens Res. 2022. PMID: 35058583 Free PMC article. Clinical Trial.
The primary assessment was a reduction in msSBP from baseline with sacubitril/valsartan 200 mg vs. olmesartan 20 mg at Week 8. Secondary assessments included msSBP reduction with sacubitril/valsartan 400 mg vs. olmesartan at Week 8 and reductions in mean sitting dia …
The primary assessment was a reduction in msSBP from baseline with sacubitril/valsartan 200 mg vs. olmesartan 20 mg at Week 8. Second …
Twenty-Four-Hour Blood Pressure-Lowering Efficacy of Sacubitril/Valsartan Versus Olmesartan in Japanese Patients With Essential Hypertension Based on Nocturnal Blood Pressure Dipping Status: A Post Hoc Analysis of Data From a Randomized, Double-Blind Multicenter Study.
Kario K, Rakugi H, Yarimizu D, Morita Y, Eguchi S, Iekushi K. Kario K, et al. J Am Heart Assoc. 2023 Apr 18;12(8):e027612. doi: 10.1161/JAHA.122.027612. Epub 2023 Apr 7. J Am Heart Assoc. 2023. PMID: 37026551 Free PMC article. Clinical Trial.
Methods and Results Data from a randomized clinical trial comparing the BP-lowering effects of 8 weeks of treatment with sacubitril/valsartan (200 or 400 mg/d) and olmesartan (20 mg/d) in Japanese patients with mild-to-moderate hypertension were analyzed. ...Both sacubitri …
Methods and Results Data from a randomized clinical trial comparing the BP-lowering effects of 8 weeks of treatment with sacubitril/valsarta …
Effects of Sacubitril/Valsartan Versus Olmesartan on Central Hemodynamics in the Elderly With Systolic Hypertension: The PARAMETER Study.
Williams B, Cockcroft JR, Kario K, Zappe DH, Brunel PC, Wang Q, Guo W. Williams B, et al. Hypertension. 2017 Mar;69(3):411-420. doi: 10.1161/HYPERTENSIONAHA.116.08556. Epub 2017 Jan 16. Hypertension. 2017. PMID: 28093466 Clinical Trial.
Patients (n=454; mean age, 67.7 years; mean seated systolic blood pressure, 158.6 mm Hg; mean seated pulse pressure, 69.7 mm Hg) were randomized to receive once-daily sacubitril/valsartan 200 mg or olmesartan 20 mg, force titrated to double the initial doses after 4 weeks, …
Patients (n=454; mean age, 67.7 years; mean seated systolic blood pressure, 158.6 mm Hg; mean seated pulse pressure, 69.7 mm Hg) were random …
The effect of sacubitril/valsartan compared to olmesartan on cardiovascular remodelling in subjects with essential hypertension: the results of a randomized, double-blind, active-controlled study.
Schmieder RE, Wagner F, Mayr M, Delles C, Ott C, Keicher C, Hrabak-Paar M, Heye T, Aichner S, Khder Y, Yates D, Albrecht D, Langenickel T, Freyhardt P, Janka R, Bremerich J. Schmieder RE, et al. Eur Heart J. 2017 Nov 21;38(44):3308-3317. doi: 10.1093/eurheartj/ehx525. Eur Heart J. 2017. PMID: 29029087 Free article. Clinical Trial.
Left ventricular mass index decreased to a greater extent in the sacubitril/valsartan group compared to the olmesartan group from baseline to 12 weeks (-6.36 vs. -2.32 g/m2; P = 0.039) and from baseline to 52 weeks (-6.83 vs. -3.55 g/m2; P = 0.029). ...There were no signif …
Left ventricular mass index decreased to a greater extent in the sacubitril/valsartan group compared to the olmesartan group from bas …
Olmesartan clinical trial in Okinawan patients under OKIDS (OCTOPUS) study: design and methods.
Iseki K, Tokuyama K, Shiohira Y, Higa A, Hirano H, Toma S, Kohagura K, Ueda S. Iseki K, et al. Clin Exp Nephrol. 2009 Apr;13(2):145-151. doi: 10.1007/s10157-008-0116-8. Epub 2008 Dec 20. Clin Exp Nephrol. 2009. PMID: 19101780 Clinical Trial.
The outcomes will be compared between two treatment regimens, such as (1) renin-angiotensin system (RAS) inhibitor Olmesartan and others, and (2) antihypertensive drugs without RAS inhibitors, in a parallel fashion. The title of the study is Olmesartan Clinical Tria …
The outcomes will be compared between two treatment regimens, such as (1) renin-angiotensin system (RAS) inhibitor Olmesartan and oth …
Efficacy and Safety of a Single-Pill Triple Combination of Olmesartan, Amlodipine, and Rosuvastatin in Hypertensive Patients with Low-to-Moderate Cardiovascular Risk: A Multicenter, Randomized, Open-Label, Active-Control, Phase IV Clinical Trial.
Kim BJ, Cha KS, Cho WH, Kim EJ, Choi SH, Kim MH, Kim SH, Park JB, Park SM, Sohn IS, Ryu KH, Chae IH. Kim BJ, et al. J Cardiovasc Pharmacol Ther. 2023 Jan-Dec;28:10742484231205204. doi: 10.1177/10742484231205204. J Cardiovasc Pharmacol Ther. 2023. PMID: 37814541 Free article. Clinical Trial.
INTRODUCTION: This study evaluated the efficacy and safety of a single-pill triple-combination of olmesartan/amlodipine/rosuvastatin (Olme/Amlo/Rosu) in comparison with a single-pill dual-combination of olmesartan/amlodipine (Olme/Amlo) in hypertensive patients with …
INTRODUCTION: This study evaluated the efficacy and safety of a single-pill triple-combination of olmesartan/amlodipine/rosuvastatin …
A Comparison Study of Olmesartan and Valsartan Effects on Myocardial Metabolism in Patients With Dilated Cardiomyopathy: the OVOID Trial.
Jo S, Park K, Choi JH, Sohn CB, Kim J, Kwon YS, Kim SH, Park TH. Jo S, et al. J Am Heart Assoc. 2025 Jul;14(13):e041406. doi: 10.1161/JAHA.125.041406. Epub 2025 Jun 27. J Am Heart Assoc. 2025. PMID: 40576039 Free PMC article. Clinical Trial.
This study aimed to evaluate effects on myocardial metabolism of the angiotensin II receptor blockers olmesartan and valsartan in patients with dilated cardiomyopathy. We hypothesized that olmesartan, owing to its stronger and longer-lasting angiotensin II receptor …
This study aimed to evaluate effects on myocardial metabolism of the angiotensin II receptor blockers olmesartan and valsartan in pat …
Heart Failure With Preserved Ejection Fraction and Lower Natriuretic Peptide: Clinical Characteristics and Change in Natriuretic Peptide Levels.
Teramoto K, Nochioka K, Sakata Y, Nishimura K, Shimokawa H, Yasuda S; SUPPORT Trial Investigators *. Teramoto K, et al. J Am Heart Assoc. 2025 Nov 4;14(21):e041208. doi: 10.1161/JAHA.125.041208. Epub 2025 Oct 23. J Am Heart Assoc. 2025. PMID: 41128146 Free PMC article. Clinical Trial.
METHODS: Using data from the SUPPORT (Supplemental Benefit of an Angiotensin Receptor Blocker in Hypertensive Patients With Stable Heart Failure Using Olmesartan) trial, we examined the temporal changes in NT-proBNP and long-term outcomes in patients with HF with preserved …
METHODS: Using data from the SUPPORT (Supplemental Benefit of an Angiotensin Receptor Blocker in Hypertensive Patients With Stable Heart Fai …
328 results